secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001171843-24-002673
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024
--------------------------------------------------------------------------------

- Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.
- Griffin receives $500K base salary, 60% target bonus, and $2M equity grant split between RSUs and stock options.
- Michael Levitz resigned as CFO on May 2; will stay through Dec 31, 2024 for transition, receiving $100K one-time payment.
- Levitz's separation includes continued salary through year-end and a general release of claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/f8k_050824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer